Skip to main content
For years HIV experts and advocates have warned that unless federal funding for the AIDS Drug Assistance Program (ADAP) was ramped up significantly then thousands of Americans could be left off the roles and face risks of illness and death without dependable access to antiretroviral therapy (ART).

ADAPs worst-case scenario arrives with a vengeance